论文部分内容阅读
关于子宫内膜癌患者绝经激素治疗(MHT)的研究尚有限,大部分医生考虑到雌激素是子宫内膜癌的重要发病因素之一,并不建议给予子宫内膜癌患者术后MHT。目前认为子宫内膜癌并不是MHT的绝对禁忌证,选择恰当的剂量和药物种类不会引起子宫内膜癌术后复发以及病死率增加,并可提高子宫内膜癌患者治疗后生存质量和起到适当保护作用。由于数据大部分来自具有选择偏差的回顾性研究或小型前瞻性非随机研究。因此,医生在评估子宫内膜癌患者术后是否需要MHT时一定要充分考虑利弊,个体化治疗。
There is limited research on menopausal hormone therapy (MHT) in patients with endometrial cancer. Most doctors consider that estrogen is one of the important pathogenetic factors of endometrial cancer, and it is not recommended to give postoperative MHT to endometrial cancer patients. Currently, endometrial cancer is not considered as an absolute contraindication to MHT. Choosing the appropriate dosage and type of drug will not cause postoperative recurrence and increased mortality of endometrial cancer, and may improve the quality of life of patients with endometrial cancer after treatment To the appropriate protection. Because most of the data comes from retrospective studies with selection bias or small prospective non-randomized studies. Therefore, doctors in assessing the need for postoperative MHT in patients with endometrial cancer must fully consider the pros and cons, individualized treatment.